Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Johnson & Johnson Should Be in Your Portfolio

By George Budwell - Mar 23, 2014 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Recent trends in the health-care sector suggest that more defensive types of stocks might be good medicine for your portfolio.

The red-hot health-care sector has started cooling off. Over the past month, the iShares Nasdaq Biotechnology Index ( IBB -0.09% ) has fallen 7.33%, and last Friday saw the sector's biggest single day loss in recent memory. Although this near 5% drop was precipitated by political machinations surrounding the pricing of Gilead's ( GILD 1.71% ) new hepatitis C drug Sovaldi, it reveals the fear that is becoming part and parcel of the sector of late, namely the formation of a potential bubble. Put another way, the entire sector dropped on a mere suggestion that some drugs may be overpriced, not an actual change in pricing structure. And underneath all the noise, you need to understand that the real reason Sovaldi's pricing is being questioned is because the demand has been astronomically high, putting significant pressure on public and private insurers alike.

While I think that historically high demand for new drugs is a good thing for biotechs in the long run, you may want to start considering more defensive companies as a means to weather the political storm, so to speak. And based on recent trends, I think the migration to more defensive plays has already begun.

Johnson & Johnson as a defensive health care stock
Johnson & Johnson ( JNJ -0.67% ) is generally considered a classic defensive health-care stock because its business is well diversified into three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Moreover, the company has been around since 1887, showing its staying power. What's notable is that shares of Johnson & Johnson have become somewhat decoupled from the trends in the broader sector, ever since health care began shooting up in 2012 to 2013. Simply put, the following chart shows that Johnson & Johnson has underperformed the broader sector in the past two years, but has started to move upward over the past month, as the broader sector has fallen.

IBB 1 Year Total Returns Chart

Reasons to add Johnson & Johnson to your health care holdings
Looking beyond sectorwide trends that may only be passing fads, I think there are a handful of good reasons to buy Johnson & Johnson that are rooted in the company's core business. On the clinical front, Johnson & Johnson has had a number of important developments occur so far this year. Last month, the U.S. Food and Drug Administration, or FDA, approved the company's blood cancer drug Imbruvica, which could see peak sales in the $6 billion to $7 billion range. And last week, Johnson & Johnson announced that a late-stage study for its three-month formulation of Invega Sustenna was halted early because of a positive efficacy outcome. Invega is already approved a top-selling treatment for schizophrenia in its once-monthly formulation, so this new formulation should help the drug gain an ever larger market share, assuming approval.

Johnson & Johnson also reported a major win on the legal front last week after an Arkansas court reversed a $1.2 billion decision against the company for fraud claims regarding its antipsychotic drug Risperdal.  

Turning to Johnson & Johnson's fundamentals, the company exited 2013 with $20.9 billion in cash and cash equivalents. What's key to understand is that is roughly a 30% increase in cash year over year. This notable increase in cash is due primarily to double-digit growth in sales for drugs like Remicade and Zytiga. As a result, we've seen the company increase its dividend consistently and this trend looks like it will continue.

Foolish wrap-up
While Celgene ( CELG ), and Gilead grabbed headlines earlier this year as top picks among Wall Street analysts, Johnson & Johnson has marched along largely unnoticed. Yet, Johnson & Johnson has handily outperformed these top picks so far this year, and may continue to do so going forward, especially if the sector weakens further. To drive this point home, Celgene has fallen more than 14% this year, and Gilead is down around 4% year to date. Johnson & Johnson, by contrast, has gained 5.49% year to date.

My view is that this diversified biotech gives investors a stable dividend, strong earnings growth over the long-term, and a long track record of outperforming broader indices such as the S&P 500. According to the company's internal metrics, Johnson & Johnson has now beaten the S&P 500 for 10 years running. So you may want to dig deeper in this "defensive" health-care stock that offers stability and growth in an increasingly turbulent market. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$157.01 (-0.67%) $-1.06
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$70.11 (1.71%) $1.18
Celgene Corporation Stock Quote
Celgene Corporation
CELG
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$150.61 (-0.09%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.